异基因造血干细胞移植受者中人类疱疹病毒6型特异性T细胞免疫研究
该前瞻性观察研究纳入208例连续接受异基因造血干细胞移植的成人患者,采用酶联免疫斑点法检测产干扰素γ的HHV-6特异性T细胞。HHV-6再激活发生于63%患者,中位时间为移植后25天,其中仅40%表现为临床相关感染。首次病毒血症检出后>4天量化的HHV-6特异性T细胞应答可预测临床相关感染(P<.0001),特异性93%、敏感性79%,均高于多克隆CD3+细胞计数。
要点
- HHV-6再激活见于63%的异基因造血干细胞移植患者,中位发生时间为移植后25天。
- 再激活患者中仅40%出现临床相关感染,定义为经典HHV-6终末器官疾病及其他可能HHV-6相关终末器官疾病。
- 首次病毒血症检出后>4天量化的HHV-6特异性T细胞应答预测临床相关感染,特异性93%、敏感性79%。
核心结论
- 异基因造血干细胞移植后HHV-6再激活常见,但仅部分表现为临床相关感染。
- 循环HHV-6特异性T细胞在病毒再激活患者中显著升高,且首次病毒血症检出后>4天量化的特异性T细胞应答可预测临床相关感染。
- 总体生存率和移植相关死亡率未受时间依赖性HHV-6再激活影响,而临床相关感染与急性移植物抗宿主病存在显著关联。
- 这些结果揭示了HHV-6在异基因造血干细胞移植中的作用,并可能影响HHV-6的监测和治疗。
研究设计与样本
- 前瞻性观察研究,纳入208例连续接受异基因造血干细胞移植的成人患者。
- 采用酶联免疫斑点法(ELISpot)定量检测产干扰素γ的HHV-6特异性T细胞。
- 临床相关感染定义为依据欧洲白血病感染会议(ECIL)指南的经典HHV-6终末器官疾病及其他可能的HHV-6相关终末器官疾病。
主要发现
- HHV-6再激活发生于63%的患者,中位时间为异基因造血干细胞移植后25天。
- 再激活患者中仅40%表现为临床相关感染。
- 多因素分析识别出HHV-6再激活的危险因素:既往异基因造血干细胞移植、移植后环磷酰胺(PT-Cy)以及时间依赖性类固醇引入。
- 使用PT-Cy和类固醇与临床相关感染相关,而较高的CD3+细胞计数似乎具有保护作用。
- 循环HHV-6特异性T细胞在病毒再激活患者中显著更高;首次病毒血症检出后>4天量化的HHV-6特异性T细胞应答预测临床相关感染(P<.0001),特异性93%、敏感性79%,均高于每微升多克隆CD3+细胞。
关键数值与推荐
- HHV-6再激活率63%,中位发生时间移植后25天。
- 再激活患者中临床相关感染占40%。
- HHV-6特异性T细胞应答预测临床相关感染的P值<.0001,特异性93%、敏感性79%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human herpesvirus 6 (HHV-6) can reactivate after allogeneic hematopoietic stem cell transplant (allo-HSCT) and may lead to severe symptoms. HHV-6-specific immune responses after HSCT are largely unexplored. We conducted a prospective observational study on 208 consecutive adult patients who received allo-HSCT to investigate HHV-6 reactivations and specific immune responses. Interferon gamma-producing HHV-6-specific T cells were quantified using enzyme-linked immunospot assay (ELISpot). HHV-6 reactivation occurred in 63% of patients, at a median of 25 days from allo-HSCT. Only 40% of these presented a clinically relevant infection, defined by the presence of classical HHV-6 end-organ diseases (EODs), based on European Conference on Infections in Leukaemia (ECIL) guidelines, and other possible HHV6-related EODs. Using multivariate analysis, we identified risk factors for HHV-6 reactivation: previous allo-HSCT, posttransplant cyclophosphamide (PT-Cy), and time-dependent steroids introduction. The use of PT-Cy and steroids were associated with clinically relevant infections, whereas higher CD3+ cell counts seemed to be protective. Interestingly, circulating HHV-6-specific T cells were significantly higher in patients with reactivated virus. Moreover, HHV-6-specific T-cell responses, quantified at >4 days after the first viremia detection, predicted clinically relevant infections (P < .0001), with higher specificity (93%) and sensitivity (79%) than polyclonal CD3+ cells per μL. Overall survival and transplant-related mortality were not affected by time-dependent HHV-6 reactivation, whereas a significant association was observed between clinically relevant infections and acute graft-versus-host disease. These results shed light on the role of HHV-6 in allo-HSCT and may affect HHV-6 monitoring and treatment.
引用
- Noviello M, Lorentino F, Xue E, et al. Human herpesvirus 6-specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients. Blood Adv. 2023. PMID: 37067947. doi:10.1182/bloodadvances.2022009274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。